Loading
The people who run funding programmes are judged on money moved and papers produced. Judge them instead on whether their portfolios match the burden of disease and whether the trials they fund finish.
Funders change the performance framework for programme staff and study sections: portfolio burden alignment, share of funded trials completing on time and publishing, replication rates of funded findings, data-sharing compliance and patient-relevant outcomes reached. Publish these metrics per programme. This is an inexpensive governance change that alters what gets steered towards funding without changing peer review itself.
Shares Burden-weighted portfolio targets for every major cancer funder, Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares Incentives reward me-too drugs and marginal gains, Cancer Research UK, National Cancer Institute (NIH).
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden, National Cancer Institute (NIH).
Shares Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).
Shares Burden-weighted portfolio targets for every major cancer funder, Funding follows fashion, not burden.
Shares Incentives reward me-too drugs and marginal gains, Funding follows fashion, not burden, Cancer Research UK, National Cancer Institute (NIH).